Risk of intracranial haemorrhage in patients with atrial fibrillation treated with novel oral anticoagulants: testing the equivalence margins between dabigratran, rivaroxaban and apixaban

Author： Messori Andrea   Maratea Dario   Fadda Valeria   Trippoli Sabrina  

Publisher： Springer Publishing Company

ISSN： 0031-6970

Source： European Journal of Clinical Pharmacology, Vol.70, Iss.4, 2014-04, pp. : 505-506

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban

By Giorgi Mariano A   Cohen Arazi Hernáán   Gonzalez Claudio D   Di Girolamo Guillermo  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 4, 2011-03 ,pp. : 567-577

Informa Healthcare

Access to resources Recommend Favorite

Rivaroxaban: Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention

By Mueck Wolfgang  

Clinical Pharmacokinetics, Vol. 50, Iss. 10, 2011-10 ,pp. : 675-686

Adis International

Access to resources Recommend Favorite

Anticoagulation in atrial fibrillation: Vitamin K antagonists or new oral anticoagulants?

By Gilfrich Hans Joachim   Schott Gisela  

PHARMAKON, Vol. 1, Iss. 4, 2013-07 ,pp. : 313-319

Govi-Verlag

Access to resources Recommend Favorite

Anticoagulants, renal failure and atrial fibrillation

By Genovesi Simonetta  

Expert Opinion on Drug Safety, Vol. 12, Iss. 1, 2013-01 ,pp. : 1-3

Informa Healthcare

Access to resources Recommend Favorite

More light at the end of the tunnel – apixaban in atrial fibrillation

By Doggrell Sheila A  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 8, 2012-08 ,pp. : 1235-1239

Informa Healthcare

Access to resources Recommend Favorite